Literature DB >> 22215763

Reduced antegrade flow in the coronary sinus is a predictor of coronary artery stenosis in hypertensive patients.

Xiaozhi Zheng1, Ping Ji, Hongwei Mao, Jianqun Hu.   

Abstract

OBJECTIVES: The purpose of this study was to evaluate the feasibility of assessing blood flow in the coronary sinus by transthoracic Doppler echocardiography for detecting coronary artery stenosis in hypertensive patients.
METHODS: Flow in the coronary sinus was studied in 105 participants who all had undergone coronary angiography: 35 nonhypertensive patients, 34 hypertensive patients without coronary artery disease (CAD), and 36 hypertensive patients with CAD. The antegrade phase of flow in the coronary sinus was analyzed and compared among the groups. Multivariate analysis for blood flow and coronary artery stenosis was done.
RESULTS: Compared with the nonhypertensive patients, the hypertensive patients without CAD had significantly higher blood flow (9.36 ± 5.94 vs 5.84 ± 2.91 mL/stroke and 584.45 ± 177.32 vs 327.68 ± 125.48 mL/min, respectively; P < .001) in the coronary sinus. Compared with the hypertensive patients without CAD, those with CAD had significantly lower blood flow (5.18 ± 0.72 vs 9.36 ± 5.94 mL/stroke and 352.51 ± 156.18 vs 584.45 ± 177.32 mL/min; P < .001) and a lower velocity time integral (13.14 ± 2.51 vs 19.85 ± 4.89 cm; P < .01). Stepwise multiple regression analysis indicated that the coronary sinus diameter, velocity time integral, and heart rate significantly correlated with the blood flow per minute in the coronary sinus in each group, and the flow per minute was the independent determinant of the percent stenosis diameter. The sensitivity, specificity, and accuracy for the prediction of severe stenosis (>70%) in the left coronary artery were 91.07%, 87.76%, and 88.49% for blood flow of less than 220 mL/min in the coronary sinus.
CONCLUSIONS: Transthoracic Doppler echocardiography can effectively depict blood flow changes in the coronary sinus, and reduced antegrade flow is a sensitive and specific predictor of coronary artery stenosis in hypertensive patients.

Entities:  

Mesh:

Year:  2012        PMID: 22215763     DOI: 10.7863/jum.2012.31.1.7

Source DB:  PubMed          Journal:  J Ultrasound Med        ISSN: 0278-4297            Impact factor:   2.153


  6 in total

1.  Prognostic significance of myocardial energy expenditure and myocardial efficiency in patients with heart failure with reduced ejection fraction.

Authors:  Mehmet S Cetin; Elif H Ozcan Cetin; Ugur Canpolat; Hatice Sasmaz; Ahmet Temizhan; Sinan Aydogdu
Journal:  Int J Cardiovasc Imaging       Date:  2017-08-14       Impact factor: 2.357

2.  Detection of coronary artery disease in diabetic hypertensive patients using conventional transthoratic echocardiography at rest.

Authors:  Jie Zhang; Ji-Xu Fan; Cheng-Bo Sun; Yan Liu; Yan Wang; Yang Guo; Hong-E Li
Journal:  Int J Cardiovasc Imaging       Date:  2015-04-01       Impact factor: 2.357

3.  Coronary sinus flow is reduced in methamphetamine abusers: a transthoracic echocardiographic study.

Authors:  Guang-Liang Wei; Xiao-Zhi Zheng; Ke-Qi Chen; Yun-Yan Shi; Lian-You Wang; Xu-Yan Tan
Journal:  Int J Cardiovasc Imaging       Date:  2018-07-21       Impact factor: 2.357

4.  Successful percutaneous coronary intervention significantly improves coronary sinus blood flow as assessed by transthoracic echocardiography.

Authors:  Radmila Lyubarova; William E Boden; Steven A Fein; Joshua Schulman-Marcus; Mikhail Torosoff
Journal:  J Echocardiogr       Date:  2017-11-07

5.  Comparison of the efficacy of conventional echocardiographic parameters in the diagnosis of significant coronary artery stenosis.

Authors:  Xiao Zhi Zheng; Bin Yang; Jing Wu
Journal:  Iran J Radiol       Date:  2015-01-01       Impact factor: 0.212

6.  Sex-specific assessment of reduced coronary sinus flow in non-hypertensive patients with coronary artery disease at rest.

Authors:  Xiao-Zhi Zheng; Bin Yang; Jing Wu
Journal:  Libyan J Med       Date:  2013-07-16       Impact factor: 1.743

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.